[1]张治国 薛智文 张卓红 张莉莉 吴艳梅.喘可治注射液雾化吸入对比肌肉注射治疗慢性阻塞性肺病急性加重期的疗效和安全性观察[J].现代中医药,2017,(06):013-15.[doi:10.13424/j.cnki.mtcm.2017.06.006]
　Zhang Zhiguo Xue Zhiwen Zhang Zhuohong Zhang Lili Wu Yanmei.Comparative Observation on Clinical Effect and Safety of Aerosol Inhalation and Intramuscular Injection of Chuankezhi in Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease[J].Modern Traditional Chinese Medicine,2017,(06):013-15.[doi:10.13424/j.cnki.mtcm.2017.06.006]
点击复制

喘可治注射液雾化吸入对比肌肉注射治疗慢性阻塞性肺病急性加重期的疗效和安全性观察()
分享到：

《现代中医药》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2017年06期
页码:
013-15
栏目:
临床研究
出版日期:
2017-11-01

文章信息/Info

Title:
Comparative Observation on Clinical Effect and Safety of Aerosol Inhalation and Intramuscular Injection of Chuankezhi in Treating Acute Exacerbation of Chronic Obstructive Pulmonary Disease
文章编号:
1672-0571(2017)06-0013-03
作者:
张治国 薛智文 张卓红 张莉莉 吴艳梅
西电集团医院呼吸内科，陕西 西安 710077
Author(s):
Zhang Zhiguo Xue Zhiwen Zhang Zhuohong Zhang Lili Wu Yanmei
Respiratory Medicine Department of Xi an XD Group Hospital,Xi an 710077,China
关键词:
喘可治注射液; 雾化吸入; 肌肉注射; 慢性阻塞性肺病
Keywords:
Chuankezhi injection;  aerosol inhalation;  intramuscular injection;  AECOPD
分类号:
Ｒ563
DOI:
10.13424/j.cnki.mtcm.2017.06.006
文献标志码:
A
摘要:
目的 对比观察喘可治注射液雾化吸入与肌肉注射治疗慢性慢性阻塞性肺病急性加重期(AECOPD)患者临床疗效和安全性。方法 选取2015年3月~2017年5月我院收治的98例AECOPD患者为研究对象,采用信封法随机分为治疗组和对照组,每组49例,所有患者均接受吸氧、止咳、平喘、抗感染及纠正酸碱平衡等常规治疗。在常规治疗基础上,对照组给予喘可治肌肉注射给药,试验组给予喘可治雾化吸入给药,疗程均为7天。观察两组的临床总有效率和不良反应发生率,治疗前后肺功能和生活质量改善程度。结果 治疗组和对照组的临床总有效率分别为69.39%和75.5 1%,不良反应发生率分别为2.04%和12.24%,差异性比较无统计学意义(P>0.05);治疗前,两组患者FEV1、FEV1/FVC、呼吸困难评分和6 min步行距离(6WMT)差异性比较无统计学意义(P>0.05),治疗7天后两组患者所有指标均显著改善,组内差异性比较均有统计学意义(P<0.05),但组间差异性比较均无统计学意义(P>0.05)。结论 喘可治注射液雾化吸入治疗AECOPD的临床疗效和安临床疗效和安全性、肺功能及生活质量改善程度均与肌肉注射相当,值得临床推广使用。
Abstract:
Objective to observe comparatively the clinical effect and safety of aerosol inhalation and intramuscular injection of Chuankezhi in Treating AECOPD.Method 98 AECOPD patients treated by Xi an XD Group Hospital from March 2015 to May 2017 were selected and randomly divided into treatment group and control group with 49 cases in each by the envelop method.All the patients received conventional therapy such as oxygen inhalation,cough relief,antiasth-ma,anti-infection and acid-base balance correction.Based on that,cases in control group were given intramuscular injection of Chuankezhi while the treatment group were given aerosol inhalation of Chuankezhi.The course for each group were 7 days.Clinical efficacy rate,incidence of adverse reactions,improvement of lung function and quality of life before and after treatment of both groups were observed.Result Clinical efficacy rates of treatment group and control group were 69.39%and 75.51%,respectively,incidences of adverse reactions of the two groups were 2.04%and 12.24%,re-spectively,the differences had no statistical significance(P>0.05).Before the treatment,the difference of FEV1,FEV1/FVC,dyspnea scores and 6WMT of the two groups had no statistical significance(P>0.05).After 7 days of treat-ment,all the indicators of the two groups had significantly improved,the difference within the same group was statistically significant(P<0.05),but the difference between the two groups had no statistical significance(P>0.05).Conclusion The clinical effect,safety,the improvement of lung function and life quality of aerosol inhalation and intramuscular injection of Chuankezhi in treating AECOPD are equivalent,and is worthy of clinical application.

参考文献/References:

[1]胡正波,陈路佳,卢海波,等.喘可治注射液治疗慢性阻塞性肺疾病的系统评价[J].中国药业,2013,22(23):9-12.
[2]朱越燕,张孝钦,薛骞.喘可治雾化治疗COPD急性发作期疗效观察[J].中药材,2015,38(4):875-877.
[3]中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67-80.
[4]脱鸣富,郭李玲,赵斌斌,等.痰热清注射液静脉滴注联合雾化吸入给药治疗中重度慢性阻塞性肺病急性加重临床疗效和经济学研究[J].中国现代应用药学杂志,2016,33(4):484-488.
[5]陈晖.多索茶碱与氨茶碱治疗COPD急性加重期患者的疗效及安全性比较[J].现代中西医结合杂志,2014,23(15):1643-1645.
[6]成人慢性气道疾病雾化吸入治疗专家组.雾化吸入疗法在呼吸疾病中的应用专家共识(2016年版)[J].中华医学杂志,2016,96(34),2696-2708.
[7]袁丽萍,周新,李洪杰,等.雾化吸入鱼腥草注射液治疗上呼吸道感染的系统评价[J].中国新药杂志,2011,20(3):284.
[8]耿丽,方宝霞,陈舒梅,等.喜炎平注射液不同给药途径治疗儿童呼吸道感染的Meta分析[J].现代中西医结合杂志,2014,23(29):3214-3216.

备注/Memo

备注/Memo:
收稿日期:2017-03-22编辑:巩振东
更新日期/Last Update: 2017-11-15